Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD3-R52H3 | Rabbit | Rabbit CD73 / NT5E Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
|
CD3-C52H5 | Canine | Canine CD73 / NT5E Protein, His Tag (MALS verified) (active enzyme) |
![]() ![]() |
||
CD3-S52H3 | Sus scrofa (Pig) | Sus scrofa CD73 / NT5E Protein, His Tag (active enzyme, MALS verified) | ![]() |
![]() ![]() |
|
MBS-K022 | Human | Human CD73-coupled Magnetic Beads | |||
CD3-C52H9 | Cynomolgus | Cynomolgus CD73 Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
![]() ![]() |
CD3-H5252 | Human | Human CD73 Protein, Mouse IgG2a Fc Tag (active enzyme) | ![]() |
![]() ![]() |
![]() ![]() |
CD3-H82E3 | Human | Biotinylated Human CD73 / NT5E Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD3-M52H9 | Mouse | Mouse CD73 / NT5E Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
|
CD3-H52H7 | Human | Human CD73 / NT5E Protein, His Tag (HPLC-verified) (active enzyme) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
Anti-CD73 antibody (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD73, His Tag (HPLC-verified) (Cat. No. CD3-H52H7) with an affinity constant of 0.164 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD73 monoclonal antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Neoplasms | Details | ||
BR-101 | BR101; BR-101 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Solid tumours | Details |
SRF-373(Surface Oncology) | SRF-373; NZV-930 | Surface Oncology | Details | ||
IPH-5301 | IPH-5301 | Phase 1 Clinical | Innate Pharma | Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Neoplasm Metastasis | Details |
IBI-325 | IBI-325 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours | Details |
INCA-00186 | INCA-00186 | Incyte Corp Ltd | Details | ||
Uliledlimab | TJ-004309; TJD-5; TJ-4309 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
BMS-986179 | BMS-986179 | Bristol-Myers Squibb Company | Details | ||
LY-3475070 | LY-3475070 | Eli Lilly And Company | Details | ||
Dalutrafusp alfa | GS-1423; AGEN-1423 | Gilead | Details | ||
PT-199 | PT-199 | Phase 1 Clinical | Phanes Therapeutics Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
Mupadolimab | CPI-006 | Phase 2 Clinical | Corvus | Head and Neck Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Papillomavirus Infections; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Urinary Bladder Neoplasms; Sarcoma; Prostatic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
PM-1015 | PM1015; PM-1015 | Phase 1 Clinical | Biotheus Inc | Solid tumours | Details |
Quemliclustat | AB-680 | Phase 2 Clinical | Arcus Biosciences Inc, Gilead Sciences Inc | Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms | Details |
Oleclumab | MEDI-9447 | Phase 3 Clinical | Medimmune Llc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung | Details |
Dresbuxelimab | AK-119 | Phase 1 Clinical | Akeso Pharmaceuticals Inc | Solid tumours; Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis | Details |
JAB-BX102 | JAB-BX102 | Phase 2 Clinical | Jacobio Pharmaceuticals Co Ltd | Solid tumours | Details |
CB-708 | CB-708; CB708; ATG-037 | Phase 1 Clinical | Calithera Biosciences Inc | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.